Searched for
GBR
Wimbledon 2025 Day 1: Alcaraz, Sabalenka, Osaka, Paolini among top stars in action; check full scheduleWimbledon 2025 kicks off with top seeds Aryna Sabalenka, Carlos Alcaraz, and Jasmine Paolini in action. Alcaraz will open play on Centre Co...- Indian men's hockey team suffers 1-3 loss to Great Britain in FIH Pro LeagueIndian men's hockey team lost 1-3 to hosts Great Britain in FIH Pro League. Harmanpreet-led side stunned world champions Germany 3-0. Bandu...
- Wimbledon Day 4 Andy Murray vs Stefanos Tsitsipas: Today's matches, complete schedule and order of playAndy Murray (GBR) vs Stefanos Tsitsipas will be facing each other in the second round at Wimbledon today. It will be the third match of the...
- Study suggests similarity between biosimilar GBR 310 and omalizumab: GlenmarkGlenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.
- Glenmark Pharma begins clinical trial of anti-myeloma drugThe additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity, it added.
- Glenmark Pharma releases investigational skin findingsGlenmark Pharma President and Chief Medical Officer Fred Grossman said atopic dermatitis can have a severe impact on quality of life and th...
- Glenmark anti-myeloma drug gets clinical trial nod from USFDAThis is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.
- FDA okays Glenmark's first-in-human study for respiratory drugAccording to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...
- Glenmark Pharmaceuticals starts studies on new drug aimed at cancer treatmentShares of Glenmark Pharmaceuticals were trading at Rs 867 in the afternoon trade, up 0.05 per cent from the previous close on BSE.
- Glenmark's novel antibody GBR 1302 to enter clinical trialsGlenmark has completed the pre-clinical evaluation for its bi-specific antibody GBR 1302 and filed the phase I trial application for the sa...
- Glenmark Pharmaceuticals completes phase I clinical trials for antibodyGlenmark Pharmaceuticals has completed the clinical phase I studies for its novel monoclonal antibody 'GBR 830' for treating autoimmune dis...
- Glenmark Pharmaceuticals discovers new molecule; enters oncology segmentGlenmark announced the discovery and initiation of studies of a novel clinical development candidate, GBR 1302, the company said in a state...
- Glenmark Pharmaceuticals' new molecule enters human trialsGlenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 is entering human trials.
- Glenmark Pharmaceuticals's monoclonal antibody for pain entering human trialsGBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).
- Glenmark initiates studies to develop new molecule 'GBR 830'Glenmark Pharmaceuticals initiates studies to develop a new molecule 'GBR 830', which could treat diseases like Arthritis (RA) and bowel di...
- Glenmark enters phase II clinical trial for new drug moleculeGlenmark Pharmaceuticals said it has entered the phase II clinical trials for its new drug molecule aimed at treating ulcerative colitis.
- Glenmark gets $25 mn from Sanofi as final upfront paymentGlenmark Pharmaceuticals today said it has received Rs 110 crore from Sanofi, as second tranche of oulicensing fee for a deal with French d...
- Glenmark receives $25 mn from Sanofi as upfront paymentFollowing that clearance, the deal has now become effective and Glenmark has also received the first upfront payment of USD 25 million, it ...
- Glenmark finds molecule for treating blood cancerGlenmark Pharmaceuticals on Thursday said it has discovered a new drug molecule which can treat blood and lymph cancer, besides inflammator...
- Glenmark to start phase I clinical trials of GBR 500 in USDrug firm Glenmark pharmaceuticals on Friday said it will file an application with American health regulator US Food and Drug Administrator...
Load More
